IFNA1 and cancer: Specifically, the pDC proficiency in producing IFN-α can be hijacked by immunosuppressive cytokines, oncometabolites, or ligands to inhibitory receptors expressed on the cell surface, thus supporting cancer progression [22] (Fig. 4).